PFIZER foi a Brasil por Teuto

The partnership will enhance Pfizer's position in Brazil by providing access to Teuto's broad portfolio of approximately 250 products, available in more than 400 presentations.

Pfizer also gains access to significant distribution networks in Brazil and the opportunity to commercialise Teuto's generic products in various markets outside the country.

Under the terms of the agreement, Pfizer will make an upfront payment of approximately $240 million and Teuto will be eligible to receive a performance-based milestone payment.

Pfizer has been looking for a strong generics firm deal for the past year, with the US-based pharma company seeking to buy German generics firmRatiopharm back in March, before being pipped to the post by Teva.

Jean-Michel Halfon, president of Pfizer's emerging markets business unit, said: “We believe this partnership will enable both companies to effectively build upon one another's core capabilities and areas of expertise to help address the needs of more patients than ever before.

“This agreement demonstrates Pfizer's commitment to pursue focused investments in key emerging markets to accelerate our growth and increase patient access to high-quality medicines.

Mas